Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
50
LZAGY Quote, Financials, Valuation and Earnings
Last price:
$66.87
Seasonality move
:
4.26%
Day range:
$65.84 - $67.23
52-week range:
$55.57 - $73.85
Dividend yield:
0.35%
P/E ratio:
40.92x
P/S ratio:
6.15x
P/B ratio:
4.40x
Volume:
45.5K
Avg. volume:
136.5K
1-year change:
4.24%
Market cap:
$46.9B
Revenue:
$7.9B
EPS (TTM):
$1.63
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LZAGY
Lonza Group AG
|
-- | -- | -- | -- | -- |
|
BPMUF
Basilea Pharmaceutica AG
|
$93.1M | -- | -- | -- | -- |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -- | -- | -- | -- |
|
ELVAF
EvoNext Holdings SA
|
-- | -- | -- | -- | -- |
|
ONC
BeOne Medicines Ltd.
|
$1.5B | $1.30 | 27.83% | 6689.47% | $409.33 |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LZAGY
Lonza Group AG
|
$66.87 | -- | $46.9B | 40.92x | $0.42 | 0.35% | 6.15x |
|
BPMUF
Basilea Pharmaceutica AG
|
$71.00 | -- | $871.3M | 19.33x | $0.00 | 0% | 3.46x |
|
CSBTF
Kuros Biosciences Ltd.
|
$32.00 | -- | $1.3B | -- | $0.00 | 0% | 9.78x |
|
ELVAF
EvoNext Holdings SA
|
$1.1700 | -- | $8.4M | 5.90x | $0.00 | 0% | 0.61x |
|
ONC
BeOne Medicines Ltd.
|
$297.04 | $409.33 | $32.9B | 117.74x | $0.00 | 0% | 6.29x |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
$21.15 | -- | $274.4M | 1.45x | $0.00 | 0% | 4.78x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LZAGY
Lonza Group AG
|
34.86% | -0.282 | -- | 0.87x |
|
BPMUF
Basilea Pharmaceutica AG
|
85.07% | 0.818 | -- | 2.96x |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -0.557 | -- | 1.61x |
|
ELVAF
EvoNext Holdings SA
|
-- | 0.078 | -- | -- |
|
ONC
BeOne Medicines Ltd.
|
31.44% | 0.327 | 5.95% | 2.98x |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
33% | -7.351 | -- | 0.51x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LZAGY
Lonza Group AG
|
-- | -- | 5.53% | 8.18% | -- | -- |
|
BPMUF
Basilea Pharmaceutica AG
|
-- | -- | -0.84% | -15.42% | -- | -- |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -- | -6.35% | -6.35% | -- | -- |
|
ELVAF
EvoNext Holdings SA
|
-- | -- | -- | -- | -- | -- |
|
ONC
BeOne Medicines Ltd.
|
$1.3B | $185.8M | 5.51% | 7.54% | 12.35% | $381.2M |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
-- | -- | 123.12% | 276.68% | -- | -- |
Lonza Group AG vs. Competitors
-
Which has Higher Returns LZAGY or BPMUF?
Basilea Pharmaceutica AG has a net margin of -- compared to Lonza Group AG's net margin of --. Lonza Group AG's return on equity of 8.18% beat Basilea Pharmaceutica AG's return on equity of -15.42%.
Company Gross Margin Earnings Per Share Invested Capital LZAGYLonza Group AG-- -- $16.6B BPMUFBasilea Pharmaceutica AG-- -- $125.1M -
What do Analysts Say About LZAGY or BPMUF?
Lonza Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Basilea Pharmaceutica AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Lonza Group AG has higher upside potential than Basilea Pharmaceutica AG, analysts believe Lonza Group AG is more attractive than Basilea Pharmaceutica AG.
Company Buy Ratings Hold Ratings Sell Ratings LZAGYLonza Group AG0 0 0 BPMUFBasilea Pharmaceutica AG0 0 0 -
Is LZAGY or BPMUF More Risky?
Lonza Group AG has a beta of 1.242, which suggesting that the stock is 24.206% more volatile than S&P 500. In comparison Basilea Pharmaceutica AG has a beta of 0.327, suggesting its less volatile than the S&P 500 by 67.337%.
-
Which is a Better Dividend Stock LZAGY or BPMUF?
Lonza Group AG has a quarterly dividend of $0.42 per share corresponding to a yield of 0.35%. Basilea Pharmaceutica AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lonza Group AG pays 29.42% of its earnings as a dividend. Basilea Pharmaceutica AG pays out -- of its earnings as a dividend. Lonza Group AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LZAGY or BPMUF?
Lonza Group AG quarterly revenues are --, which are smaller than Basilea Pharmaceutica AG quarterly revenues of --. Lonza Group AG's net income of -- is lower than Basilea Pharmaceutica AG's net income of --. Notably, Lonza Group AG's price-to-earnings ratio is 40.92x while Basilea Pharmaceutica AG's PE ratio is 19.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lonza Group AG is 6.15x versus 3.46x for Basilea Pharmaceutica AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LZAGYLonza Group AG6.15x 40.92x -- -- BPMUFBasilea Pharmaceutica AG3.46x 19.33x -- --
-
Which has Higher Returns LZAGY or CSBTF?
Kuros Biosciences Ltd. has a net margin of -- compared to Lonza Group AG's net margin of --. Lonza Group AG's return on equity of 8.18% beat Kuros Biosciences Ltd.'s return on equity of -6.35%.
Company Gross Margin Earnings Per Share Invested Capital LZAGYLonza Group AG-- -- $16.6B CSBTFKuros Biosciences Ltd.-- -- $65M -
What do Analysts Say About LZAGY or CSBTF?
Lonza Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Kuros Biosciences Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Lonza Group AG has higher upside potential than Kuros Biosciences Ltd., analysts believe Lonza Group AG is more attractive than Kuros Biosciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings LZAGYLonza Group AG0 0 0 CSBTFKuros Biosciences Ltd.0 0 0 -
Is LZAGY or CSBTF More Risky?
Lonza Group AG has a beta of 1.242, which suggesting that the stock is 24.206% more volatile than S&P 500. In comparison Kuros Biosciences Ltd. has a beta of 0.916, suggesting its less volatile than the S&P 500 by 8.447%.
-
Which is a Better Dividend Stock LZAGY or CSBTF?
Lonza Group AG has a quarterly dividend of $0.42 per share corresponding to a yield of 0.35%. Kuros Biosciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lonza Group AG pays 29.42% of its earnings as a dividend. Kuros Biosciences Ltd. pays out -- of its earnings as a dividend. Lonza Group AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LZAGY or CSBTF?
Lonza Group AG quarterly revenues are --, which are smaller than Kuros Biosciences Ltd. quarterly revenues of --. Lonza Group AG's net income of -- is lower than Kuros Biosciences Ltd.'s net income of --. Notably, Lonza Group AG's price-to-earnings ratio is 40.92x while Kuros Biosciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lonza Group AG is 6.15x versus 9.78x for Kuros Biosciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LZAGYLonza Group AG6.15x 40.92x -- -- CSBTFKuros Biosciences Ltd.9.78x -- -- --
-
Which has Higher Returns LZAGY or ELVAF?
EvoNext Holdings SA has a net margin of -- compared to Lonza Group AG's net margin of --. Lonza Group AG's return on equity of 8.18% beat EvoNext Holdings SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LZAGYLonza Group AG-- -- $16.6B ELVAFEvoNext Holdings SA-- -- -- -
What do Analysts Say About LZAGY or ELVAF?
Lonza Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand EvoNext Holdings SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Lonza Group AG has higher upside potential than EvoNext Holdings SA, analysts believe Lonza Group AG is more attractive than EvoNext Holdings SA.
Company Buy Ratings Hold Ratings Sell Ratings LZAGYLonza Group AG0 0 0 ELVAFEvoNext Holdings SA0 0 0 -
Is LZAGY or ELVAF More Risky?
Lonza Group AG has a beta of 1.242, which suggesting that the stock is 24.206% more volatile than S&P 500. In comparison EvoNext Holdings SA has a beta of -40.297, suggesting its less volatile than the S&P 500 by 4129.699%.
-
Which is a Better Dividend Stock LZAGY or ELVAF?
Lonza Group AG has a quarterly dividend of $0.42 per share corresponding to a yield of 0.35%. EvoNext Holdings SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lonza Group AG pays 29.42% of its earnings as a dividend. EvoNext Holdings SA pays out -- of its earnings as a dividend. Lonza Group AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LZAGY or ELVAF?
Lonza Group AG quarterly revenues are --, which are smaller than EvoNext Holdings SA quarterly revenues of --. Lonza Group AG's net income of -- is lower than EvoNext Holdings SA's net income of --. Notably, Lonza Group AG's price-to-earnings ratio is 40.92x while EvoNext Holdings SA's PE ratio is 5.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lonza Group AG is 6.15x versus 0.61x for EvoNext Holdings SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LZAGYLonza Group AG6.15x 40.92x -- -- ELVAFEvoNext Holdings SA0.61x 5.90x -- --
-
Which has Higher Returns LZAGY or ONC?
BeOne Medicines Ltd. has a net margin of -- compared to Lonza Group AG's net margin of 4.44%. Lonza Group AG's return on equity of 8.18% beat BeOne Medicines Ltd.'s return on equity of 7.54%.
Company Gross Margin Earnings Per Share Invested Capital LZAGYLonza Group AG-- -- $16.6B ONCBeOne Medicines Ltd.88.43% $0.58 $6.4B -
What do Analysts Say About LZAGY or ONC?
Lonza Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $409.33 which suggests that it could grow by 37.8%. Given that BeOne Medicines Ltd. has higher upside potential than Lonza Group AG, analysts believe BeOne Medicines Ltd. is more attractive than Lonza Group AG.
Company Buy Ratings Hold Ratings Sell Ratings LZAGYLonza Group AG0 0 0 ONCBeOne Medicines Ltd.17 0 1 -
Is LZAGY or ONC More Risky?
Lonza Group AG has a beta of 1.242, which suggesting that the stock is 24.206% more volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.532, suggesting its less volatile than the S&P 500 by 46.826%.
-
Which is a Better Dividend Stock LZAGY or ONC?
Lonza Group AG has a quarterly dividend of $0.42 per share corresponding to a yield of 0.35%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lonza Group AG pays 29.42% of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend. Lonza Group AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LZAGY or ONC?
Lonza Group AG quarterly revenues are --, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.5B. Lonza Group AG's net income of -- is lower than BeOne Medicines Ltd.'s net income of $66.8M. Notably, Lonza Group AG's price-to-earnings ratio is 40.92x while BeOne Medicines Ltd.'s PE ratio is 117.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lonza Group AG is 6.15x versus 6.29x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LZAGYLonza Group AG6.15x 40.92x -- -- ONCBeOne Medicines Ltd.6.29x 117.74x $1.5B $66.8M
-
Which has Higher Returns LZAGY or SPHDF?
Santhera Pharmaceuticals Holding AG has a net margin of -- compared to Lonza Group AG's net margin of --. Lonza Group AG's return on equity of 8.18% beat Santhera Pharmaceuticals Holding AG's return on equity of 276.68%.
Company Gross Margin Earnings Per Share Invested Capital LZAGYLonza Group AG-- -- $16.6B SPHDFSanthera Pharmaceuticals Holding AG-- -- $79.8M -
What do Analysts Say About LZAGY or SPHDF?
Lonza Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Santhera Pharmaceuticals Holding AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Lonza Group AG has higher upside potential than Santhera Pharmaceuticals Holding AG, analysts believe Lonza Group AG is more attractive than Santhera Pharmaceuticals Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings LZAGYLonza Group AG0 0 0 SPHDFSanthera Pharmaceuticals Holding AG0 0 0 -
Is LZAGY or SPHDF More Risky?
Lonza Group AG has a beta of 1.242, which suggesting that the stock is 24.206% more volatile than S&P 500. In comparison Santhera Pharmaceuticals Holding AG has a beta of -0.872, suggesting its less volatile than the S&P 500 by 187.184%.
-
Which is a Better Dividend Stock LZAGY or SPHDF?
Lonza Group AG has a quarterly dividend of $0.42 per share corresponding to a yield of 0.35%. Santhera Pharmaceuticals Holding AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lonza Group AG pays 29.42% of its earnings as a dividend. Santhera Pharmaceuticals Holding AG pays out -- of its earnings as a dividend. Lonza Group AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LZAGY or SPHDF?
Lonza Group AG quarterly revenues are --, which are smaller than Santhera Pharmaceuticals Holding AG quarterly revenues of --. Lonza Group AG's net income of -- is lower than Santhera Pharmaceuticals Holding AG's net income of --. Notably, Lonza Group AG's price-to-earnings ratio is 40.92x while Santhera Pharmaceuticals Holding AG's PE ratio is 1.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lonza Group AG is 6.15x versus 4.78x for Santhera Pharmaceuticals Holding AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LZAGYLonza Group AG6.15x 40.92x -- -- SPHDFSanthera Pharmaceuticals Holding AG4.78x 1.45x -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
34
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
54
KORU alert for Mar 4
Direxion Daily MSCI South Korea Bull 3X Shares [KORU] is down 31.47% over the past day.
Sell
30
HROW alert for Mar 4
Harrow, Inc. [HROW] is down 27.92% over the past day.
Sell
28
GDXD alert for Mar 4
MicroSectors Gold Miners -3X Inverse Leveraged ETN [GDXD] is up 26.18% over the past day.
